Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy

Brindl, Niall; Boekhoff, Henning; Bauer, Andrea S.; Gaida, Matthias M.; Dang, Hien; Kaiser, Jörg; Hoheisel, Jörg D.; Felix, Klaus

doi:10.3390/cancers14153562

Cited by 3 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps a combination of marker testing can improve the outcomes [ 68 ]. Among 249 full-length recombinant human protein microarrays, 14 autoreactive proteins (autoantibodies) were identified as potential biomarkers for low-grade or high-grade IPMNs [ 69 ]. Protein analysis of pancreatic juice or cystic fluid included CEA, monoclonal antibody (mAb) Das-1 and amylase.…”

Section: Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review

Pavlidis

Sapalidis²,

Pavlidis³

2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

Intraductal papillary mucinous neoplasms (IPMNs) account for approximately 35% of all cystic tumors in the pancreas and represent the largest subgroup. They are characterized by mucin production and intraductal papillary epithelium growth. IPMNs range from benign to malignant lesions. Biomarkers combined with 18F-Fluorodeoxyglucose–positron emission tomography (18FDG–PET) is the best diagnostic tool. The risk of malignant transformation for main-duct IPMNs is between 34–68% and for low-risk branch-duct (BD)-IPMNs it is 1.1%. Monitoring is crucial for determining the optimal time of surgical excision. Novel artificial intelligence combining clinical, tumor biomarkers, imaging and molecular genomics plays a determinant role in the evaluation of such lesions. The first diagnostic tool is multidetector helical computed tomography (MDHCT) or up-to-date magnetic resonance imaging (MRI). MRI detects malignancy by enhancing mural nodules ≥3 mm. Novel endosonographic interventional techniques have been added to the diagnostic armamentarium. Pancreatoscopy is feasible and effective but challenging for evaluating the diagnosis, invasiveness, and extent of IPMNs. Its findings may change the surgical approach. Pancreatic juice and duodenal fluid have been used recently for molecular biological analysis. The genes most frequently altered include Kirsten rat sarcoma viral proto-oncogene (KRAS), tumor protein p53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), SMAD family member 4 (SMAD4), and guanine nucleotide-binding protein, alpha stimulating (GNAS). Despite the advances in diagnostic modalities, assessment of this premalignant lesion of pancreatic cancer, with its poor prognosis, is a challenging task. Pancreatectomy is the indicated approach for malignant or high-risk IPMNs with potent malignancy. Conservative management or enucleation for preserving the pancreas of low-risk BD-IPMNs is recommended, but long-term follow-up for recurrence is necessary. The management of IPMNs must be individualized based on preoperative high-risk stigmata and worrisome features.

show abstract

Section: Biomarkersmentioning

confidence: 99%

“…Among 249 full-length recombinant human protein microarrays, 14 autoreactive proteins (autoantibodies) were identified as potential biomarkers for low-grade or high-grade IPMNs [69].…”

Section:  Diagnosismentioning

confidence: 99%

Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review

Pavlidis

Sapalidis²,

Pavlidis³

2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“…The mechanisms by which autoantibodies are produced with the development of cancer are complex and difficult to understand. The immune system may initate immunologic processes causing autoantibody production in response to mutations, overexpression and modification of proteins, altered antigen folding, aberrant degradation, and so on [11]. Tumor is a unique molecular entity originally from malignant transformation of normal cells, and this transformation process is driven by mutations in multiple genes [12].…”

mentioning

confidence: 99%

Evaluation of multiple autoantibodies to tumor-associated antigens as potential diagnostic markers for pancreatic cancer

Wang,

Qiu,

Qin

et al. 2024

J Gastroenterol Res Pract

View full text Add to dashboard Cite

The aim of the study is to evaluate the clinical significance of autoantibodies to GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN in Pancreatic Cancer (PC). A total of 33 sera from PC patients and 45 sera from Normal Controls (NC) were enrolled to measure nine autoantibodies by Enzyme-Linked Immunosorbent Assay (ELISA). Multiple parameters in individual or combination forms were applied for evaluation. The level of all autoantibodies except anti-GNAS and anti-Calnuc was significantly higher in PC patients than that in normal controls. Significantly increased frequencies were found for four autoantibodies to MSLN, p16, PTEN and Sui1 at 75.8%, 66.7%, 30.3% and 27.3% compared to normal controls (4.9%). The ability of these autoantibodies to distinguish PC patients from normal controls reflected by the area under ROC curve (AUC) ranged from 0.666 to 0.884, with anti-p16 (0.884 of AUC) and anti-MSLN (0.857 of AUC) showing the strongest diagnostic performance. The combination of anti-MSLN and anti-p16 could improve the diagnostic sensitivity. In addition, two autoantibodies to MSLN and Sui1 in PC patients decreased after chemotherapy. Four autoantibodies to MSLN, p16, Sui1, PTEN showed potential diagnostic markers for pancreatic cancer, with anti-MSLN and anti-p16 in best performance. The combination of these two autoantibodies showed the most economical and practical potential. The significance of the reduction of autoantibodies to MSLN and Sui1 in PC patients who were subjected to chemotherapy needs to be further explored.

show abstract

Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology

Beutgen,

Shinkevich,

Pörschke

et al. 2024

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy

Cited by 3 publications

References 57 publications

Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review

Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review

Evaluation of multiple autoantibodies to tumor-associated antigens as potential diagnostic markers for pancreatic cancer

Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology

Contact Info

Product

Resources

About